Appointment of Nomad and Broker

Oxford Pharmascience Group plc

("Oxford Pharmascience" or "the Company")

Appointment of Nomad and Broker

Oxford Pharmascience is pleased to announce the appointment of N+1 Singer Advisory LLP ("N+1 Singer") as the Company's nominated adviser and broker with immediate effect.

Enquiries:

Oxford Pharmascience Group plc

Nigel Theobald, Chief Executive +44 1865 854 874

N+1 Singer

Shaun Dobson/Jenny Wyllie +44 203 205 7631

About Oxford Pharmascience Group Plc

Oxford Pharmascience Group Plc develops advanced yet practical pharmaceutical technologies to enable reformulation that adds value to off patent and soon to be off patent drugs. The Company does not manufacture or sell its own pharmaceutical products but instead seeks to license its technologies to a network of partners, mainly leading pharmaceutical companies with Rx (prescription) and OTC (Over the Counter) branded portfolios. These partners use our technologies to reposition their products helping them sustain market share and profitability by delivering improved health outcomes and/or clinical profiles via reformulated versions of the same API (active pharmaceutical ingredient).

Oxford Pharmascience Group Plc develops platform technologies that have application across multiple drug categories and can be leveraged across a broad range of reformulation problems. This business model allows us to provide solutions across the industry and fund the ongoing development of cutting edge technologies to better serve the needs of our partners. The partner companies who adopt our technology pay an up-front license fee followed by development milestone payments and then royalties on finished products sold using the technology. OXP invests the upfront licence fee to optimise product development and to ensure seamless technology transfer to the pharmaceutical partner.